Autoantibodies to IL-12 in myasthenia gravis patients with thymoma; effects on the IFN-γ responses of healthy CD4+ T cells

Journal of Neuroimmunology

Volumn 139, Issue 1-2, 2003, Pages 102-108

  Zhang, W ^a   Liu, J L ^a,c   Meager, A ^b   Newsom Davis, J ^a   Willcox, N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c People's Hospital   (China)

Author keywords

Cytokine balance; IFN ; Immunocompromised; Myasthenia gravis; Th1 Th2 balance; Thymoma

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; CD4 ANTIGEN; GAMMA INTERFERON; POLYSACCHARIDE;

ADULT; AGED; ARTICLE; CELL ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; INFECTION; MYASTHENIA GRAVIS; PRIORITY JOURNAL; T LYMPHOCYTE; THYMOMA;

EID: 0038207976     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(03)00136-X     Document Type: Article

References (45)

1. Aarli J.A., Stefansson K., Marton L.S.G., Wollman R.L. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin. Exp. Immunol. 82:1990;284-828.
2. Asherson G.L., Webster A.D.B. Thymoma and immunodeficiency. Asherson G.L., Webster A.D.B. Diagnosis and Treatment of Immunodeficiency. 1980;78-98 Blackwell, Oxford.
3. Belardelli F., Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today. 17:1996;369-372.
4. + T cells. J. Exp. Med. 178:1993;1655-1663.
5. Buckley C., Newsom-Davis J., Willcox N., Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology. 57:2001;1579-1582.
6. Cella M., Scheidegger D., Palmer-Lehmann K., Lane P., Lanzavecchia A., Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:1996;747-752.
7. Colonna M., Krug A., Cella M. Interferon-producing cells: on the front line in immune responses against pathogens. Curr. Opin. Immunol. 14:2002;373-379.
8. Decken K., Köhler G., Palmer-Lehman K., Wunderlin A., Mattner F., Magram J., Gately M.K., Alber G. Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect. Immun. 66:1998;4994-5000.
9. de Jong R., Altare F., Haagen I.-A., Elferink D.G., Boer T., van Breda Vriesman P.J., Kabel Draisma J.M., van Dissel J.T., Kroon F.P., Casanova J.L., Ottenhof T.H. Severe mycobacterial and Salmonella infections in IL-12 receptor-deficient patients. Science. 280:1998;1435-1438.
10. Drachman D.B. Myasthenia gravis. N. Engl. J. Med. 330:1994;1797-1810.
11. Fieschi C., Dupuis S., Catherinot E., Feinberg J., Bustamante J., Breiman A.et al. Low penetrance, broad resistance, and favorable outcome of interleukin-12 receptor-deficiency: medical and immunological implications. J. Exp. Med. 197:2003;527-535.
12. Genain C.P., Abel K., Belmar N., Villinger F., Rosenberg D.P., Linington C., Raine C.S., Hauser S.L. Late complications of immune deviation therapy in a nonhuman primate. Science. 274:1996;2054-2057.
13. Gresser I. Anti-tumour effects of interferons: past, present and future. Br. J. Haematol. 79(Suppl. 1):1991;1-5.
14. Gresser I., Belardelli F. Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev. 13:2002;111-118.
15. Holland S.M. Immunotherapy of mycobacterial infections. Semin. Respir. Infect. 16:2001;47-59.
16. Ito T., Amakawa R., Kaisho T., Hemmi H., Tajima K., Uehira K., Ozaki Y., Tomizawa H., Akira S., Fukuhara S. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J. Exp. Med. 195:2002;1507-1512.
17. Kadowaki N., Antonenko S., Lau J.Y., Liu Y.-J. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J. Exp. Med. 192:2000;219-226.
18. Lammas D.A., Casanova J.-L., Kumararatne D.S. Clinical consequences of defects in the IL-12-dependent interferon-gamma (IFN-γ) pathway. Clin. Exp. Immunol. 121:2000;417-425.
19. Lane P.L., Burdet C., McConnell F., Lanzavecchia A., Padovan E. CD40 ligand independent B cell activation revealed by CD40 ligand-deficient T cell clones: evidence for distinct activation requirements for antibody formation and B cell proliferation. Eur. J. Immunol. 25:1995;1788-1793.
20. Magram J., Connaughton S.E., Warrier R.R., Carvajal D.M., Wu C.Y., Ferrante J., Stewart C., Sarmiento U., Faherty D.A., Gately M.K. IL-12-deficient mice are defective in IFN-γ production and type 1 cytokine responses. Immunity. 4:1996;471-481.
21. Manetti R., Parronchi P., Giudizi M.G., Piccinni M.P., Maggi E., Trinchieri G., Romagnani S. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177:1993;1199-1204.
22. Manetti R., Annunziato F., Tomasevic L., Gianno V., Parronchi P., Romagnani S., Maggi E. Polyinosinic acid: polycytidylic acid promotes T helper type 1-specific immune responses by stimulating macrophage production of interferon-α and interleukin-12. Eur. J. Immunol. 25:1995;2656-2660.
23. Marx A., Müller-Hermelink H.-K. From basic immunobiology to the upcoming WHO-classification of tumors of the thymus. Pathol. Res. Pract. 195:1999;515-533.
24. Meager A., Willcox N., Vincent A., Newsom-Davis J. Spontaneous neutralising antibodies to interferon-alpha and interleukin-12 in thymoma-associated autoimmune disease. Lancet. 350:1997;1596-1597.
25. Meager A., Wadhwa M., Bird C., Thorpe R., Newsom-Davis J., Willcox N. Spontaneously occurring neutralising antibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with autoimmune disease. Immunology. 97:1999;526-532.
26. Meager A., Wadhwa M., Dilger P., Bird C., Thorpe R., Newsom-Davis J., Willcox N. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against Interferon-alpha, Interferon-omega and Interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin. Exp. Immunol. 132:2003;128-136.
27. Moiola L., Galbiati F., Martino G., Amadio S., Brambilla E., Comi G., Vincent A., Grimaldi L.M., Adorini L. IL-12 is involved in the induction of experimental auto-immune myasthenia gravis, an antibody-mediated disease. Eur. J. Immunol. 28:1998;2487-2497.
28. H2 development. Nat. Immunol. 1:2000;199-205.
29. Mygland Å., Aarli J.A., Matre R., Gilhus N.E. Ryanodine receptor antibodies related to severity of associated myasthenia gravis. J. Neurol. Neurosurg. Psychiatry. 57:1994;843-846.
30. Nagvekar N., Moody A.-M., Moss P., Roxanis I., Curnow J., Beeson D., Pantic N., Newsom-Davis J., Vincent A., Willcox N. A pathogenetic role for the thymoma in myasthenia gravis: autosensitization of IL-4-producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes. J. Clin. Invest. 101:1998;2268-2277.
31. Netea M.G., Stuyt R.J., Kim S.H., van der Meer J.W., Kulberg B.J., Dinarello C.A. The role of endogenous interleukin (IL)-18, IL-12, IL-1beta and tumor necrosis factor-alpha in the production of interferon-gamma induced by Candida albicans in human whole blood cultures. J. Infect. Dis. 185:2002;963-970.
32. Panitch H.S., Hirsch R.L., Haley A.S., Johnson K.P. Exacerbations of multiple sclerosis in patients treated with IFN-γ Lancet. i:1987;893-895.
33. Park A.Y., Hondowicz B., Kopf M., Scott P. The role of IL-12 in maintaining resistance to Leishmania major. J. Immunol. 168:2002;5771-5777.
34. Rönnblom L., Alm G.V. A pivotal role for the natural interferon α-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J. Exp. Med. 194:2001;F59-F63.
35. Rosai J., Levine G.D. Tumors of the thymus. Atlas of Tumor Pathology. Fascicle. vol. 13:1976;US Armed Forces Institute of Pathology. 2nd series.
36. Rowland L.P., Griffiths C.O., Kabat E.A. Myasthenia gravis, thymoma and crypto-coccal meningitis. N. Engl. J. Med. 273:1965;620-627.
37. Salio M., Cella M., Suter M., Lanzavecchia A. Inhibition of dendritic cell maturation by herpes simplex virus. Eur. J. Immunol. 29:1999;3245-3253.
38. Seder R.A., Kelsall B.L., Jankovic D. Differential roles for IL-12 in the maintenance of immune responses in infectious versus autoimmune disease. J. Immunol. 157:1996;2745-2748.
39. Shiono H., Roxanis I., Zhang W., Sims G.P., Meager A., Jacobson L.W., Liu J.-L., Matthews I., Wong Y.-L., Bonifati M., Micklem K., Stott D.I., Todd J.A., Beeson D., Vincent A., Willcox N. Scenarios for autoimmunization of T and B cells in myasthenia gravis. Ann. N.Y. Acad. Sci. 2003;. (in press).
40. Trinchieri G. Interleukin12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 70:1998;83-243.
41. Wang X., Mosmann T. In vivo priming of CD4 T cells that produce Interleukin (IL)-2 but not IL-4 or Interferon-gamma (IFN-γ), and can subsequently differentiate into IFN-γ- or IL-4-secreting cells. J. Exp. Med. 194:2001;1069-1080.
42. Willcox N. Myasthenia gravis. Curr. Opin. Immunol. 5:1993;910-917.
43. Willcox N., Schluep M., Ritter M.A., Schuurman H.-J., Newsom-Davis J., Christensson B. Myasthenic and non-myasthenic thymoma: an expansion of a minor cortical epithelial subset? Am. J. Pathol. 127:1987;447-460.
44. Williams C.L., Lennon V.A. Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational antibodies reacting with myosin, alpha-actinin or actin. J. Exp. Med. 164:1986;1043-1059.
45. Yamamoto A.-M., Gajdos P., Eymard B., Tranchant C., Warter J.M., Gomez L., Bourquin C., Bach J.-F., Garchon H.-J. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of non-thymoma patients. Arch. Neurol. 58:2001;885-890.